Open

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

The purpose of this study is to test whether the combination treatment of ONC201 and Atezolizumab is safe for the treatment of endometrial cancer.

Age & Gender

18 years ~ 99 years
Female

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

This study aims to treat your cancer and closely resembles routine care that would be received regardless of participating on a research study. To participate on the study, you will frequently meet with a member of the study team in addition to your oncology care team. The study involves blood collection and blood tests; CT scan and MRI, physical exams, study drugs, questionnaires.

Incentives

In-person visits:
up to 16

Total length of participation:
up to 2 years

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with metastatic or recurrent Endometrial Cancer
Your endometrial cancer has progressed with confirmation from scans after at least one line of chemotherapy if your disease is metastatic or your endometrial cancer

Not eligible if:

You have previously received the study drug, ONC201.
You have a history of or active autoimmune disease
You have received another investigational agent or are participating in another clinical trial within the last 28 days
you are unable to swallow the study medication, ONC201, in either capsule or Gatorade formulation
you are pregnant, breastfeeding, or plan to become pregnant within the time of the study

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Victoria Bae-Jump
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Uterine (endometrial))

IRB Number

22-0822

ClinicalTrials.gov

NCT05542407

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.